Fig. 4
New-onset AF risk in patients with T2DM in different categories of baseline BMI and BW loss after SGLT2i treatment. Cumulative incidence risk of new-onset AF for T2DM patients in different categories of baseline BMI and BW loss following SGLT2i treatment. a Compared with those with a baseline BMI of < 23 kg/m2, AF risk significantly increased at baseline BMI \(\ge\) 27.5 kg/m2 after multivariate adjustment (P for trend = 0.015). Compared with those without BW loss after 12 weeks of SGLT2i treatment, AF risk significantly decreased at a BW loss of \(\ge\) 5.0% after multivariate adjustment (P for trend = 0.004). b *Risk of outcome was adjusted for age, sex, different SGLT2i drugs and dosage, baseline comorbidities as shown in Tables 1, 2, HbA1c, eGFR, and use of antiplatelet therapy, statin, angiotensin system inhibitor, and all anti-hypoglycemic agents. AF: atrial fibrillation; CI: confidence interval; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin A1c; aHR: adjusted hazard ratio; SGLT2i: sodium–glucose cotransporter 2 inhibitor; T2DM: type 2 diabetes mellitus; BMI: body mass index; BW: body weight; SE: standard error; MRA: mineralocorticoid receptor antagonist; TZD: thiazolidinedione